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It has long been appreciated that genetic analysis of fetal or trophoblast cells in maternal blood could revolutionize prenatal diagnosis.
We implemented a protocol for single circulating trophoblast (SCT) testing using positive selection by magnetic-activated cell sorting
and single-cell low-coverage whole-genome sequencing to detect fetal aneuploidies and copy-number variants (CNVs) at 1 Mb reso-
lution. In 95 validation cases, we identified on average 0.20 putative trophoblasts/mL, of which 55% were of high quality and scorable
for both aneuploidy and CNVs. We emphasize the importance of analyzing individual cells because some cells are apoptotic, in S-phase,
or otherwise of poor quality. When two or more high-quality trophoblast cells were available for singleton pregnancies, there was com-
plete concordance between all trophoblasts unless there was evidence of confined placental mosaicism. SCT results were highly concor-
dant with available clinical data from chorionic villus sampling (CVS) or amniocentesis procedures. Although determining the exact
sensitivity and specificity will requiremore data, this study further supports the potential for SCT testing to become a diagnostic prenatal
test.Introduction
Circulating cells from the fetus or placenta in a pregnant
woman’s blood—primarily trophoblasts and nucleated
fetal red blood cells (fnRBCs)—have long been appreciated
as potential targets for noninvasive prenatal testing (NIPT)
and diagnosis. Upon isolation, these cells provide a pure
source of fetal genomic DNA, whereas in the current fetal
cell-free DNA (cfDNA)-based test (‘‘cell-free NIPT’’) the fetal
fraction only contributes 5% to 20% of the total cfDNA,
thus hindering the resolution, specificity, and utility of
the test. In addition, several factors, such as maternal ma-
lignancies, maternal chromosomal mosaicism, maternal
copy-number variants (CNVs), maternal body mass index
(BMI), and maternal organ transplants, can substantially
affect the data. This can compromise the test result, lead-
ing to false-positive aneuploidy or CNV results and, more
rarely, false-negative results.1–4 Hence, cell-free NIPT is
considered a screening test requiring diagnostic confirma-
tion, whereas cell-based NIPT has the potential to become
a diagnostic test.
The primary challenge for cell-based NIPT is that the
target cells are exceedingly rare at 1–2 cells/mL maternal
blood,5 and there is considerable inter-individual vari-
ability in the number of recoverable cells. However, despite
the fact that the relative scarcity of these cells makes their
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Although much of our work has utilized a maternal-
white-blood-cell-depletion method to enrich for target-
cell candidates,6,9 we have also collaborated on a positive
enrichment strategy using magnetic-activated cell sorting
(MACS).7 In this report, we have returned to positive selec-
tion with MACS. We found that the positive selection
method was simpler and recovered slightly greater
numbers of trophoblasts. Here, we have performed the
largest study to date and two validation studies in which
this positive trophoblast selection was applied serially to
a set of maternal venous blood samples that were subse-
quently analyzed by whole-genome sequencing for
genome-wide CNV analysis. Given the potential variation
in the quality of singlecells,9 we opted to analyze each cell
individually, unless they were present in a cell cluster that
did not dissociate during the cell-picking process. Clusters
include doublets where the two cells often appear as pairs
of mirror images, possibly being two daughter cells from a
recent cell division. Some higher-order clusters were seen,
and we assume that these cell clusters came free of the
placenta as a cluster as opposed to having been formed
as aggregates while in the circulation. This also allows for
adequate genotyping to confirm the fetal origin of each
cell and to potentially distinguish different genetic signa-
tures in twin or higher-multiple pregnancies or in thee, Houston, TX 77030, USA; 2Baylor Genetics, Houston, TX 77021, USA;
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case of confined placental mosaicism. Hence, we refer to
our assay as single circulating trophoblast (SCT) testing
hereafter.Material and Methods
Sample Collection
After informed consent was obtained, blood samples from preg-
nant women were collected in accordance with the ethical stan-
dards of the responsible committee on human experimentation
under a protocol approved by the institutional review boards of
Baylor College of Medicine and Columbia University. Virtually
any woman presenting for prenatal care was eligible for inclusion,
although there was some preference for women in their first-
trimester. Women were excluded only if blood draw was not
possible. Most of the women were recruited in Houston when be-
ing seen in clinic for genetic counseling and decision making
regarding prenatal testing. In New York, pregnant women were re-
cruited at the time of an appointment for CVS or amniocentesis.
The range of gestational age is given in Table 1 and listed specif-
ically for every sample in Table S1. For study 1, maternal blood
samples were collected in three 10 mL EDTA vacutainer tubes
(for trophoblast cell enrichment) and one 4 mL tube (for extrac-
tion of maternal genomic [g] DNA and fetal cf.DNA for fetal sex
determination). For study 2, the volume was increased to four
10 mL tubes and one 4 mL tube,. Whenever available, paternal
samples (saliva or 2 mL EDTA) were collected. Samples collected
at the Columbia recruitment site were shipped overnight to Hous-
ton at ambient temperature to be processed the next day. Tables 1
and S1 give both a summarized and detailed overview, respec-
tively, of all sample information for both studies. Control samples
from healthy, non-pregnant individuals were collected for
lymphoblast spike-in experiments.Genomic DNA Extraction and Fetal Sex Determination
Maternal and, when available, paternal gDNA was extracted from
whole blood on a MagnaPure platform (Roche) via a MagnaPure
compact nucleic acid isolation kit I. If saliva from the father was
available, gDNA was extracted with a MagnaPure compact nucleic
acid isolation kit I, large volume, on the same platform.
Fetal cfDNA was extracted from maternal plasma on the afore-
mentioned platform as well, also via the large volume kit. This
cfDNAwas used in a Y chromosome qPCR reaction so that the fetal
sex could be determined on the basis of the detection two ampli-
cons for DYS14 and SRY, as has been described.6,9Trophoblast Enrichment
Blood processing was started at most 24 h after sample collec-
tion, except for one sample for which transport was delayed
and processing started 2 days after collection. In a first step,
the blood sample underwent a 10-min fixation by the addition
of a 0.673 volume of 5% paraformaldehyde in PBS. Subse-
quently, the red blood cells were lysed by incubating for 8 min
with 103 the original blood volume of red blood cell (RBC) lysis
buffer containing 0.12% Triton X-100 in PBS. These two initial
incubations took place at room temperature on a tube roller
(20 rolls/min). Then 53 original blood volume of PBS containing
2% BSA was added. The sample was centrifuged (700 3 g,
15 min, 4C) in two 500 mL bottles, and the supernatant was
aspirated down to a final volume of 5 mL per bottle. The remain-The American Jouring cell pellets were combined, underwent two washing steps
with PBS, and were reduced to 1 mL in PBS; then a 3 mL
MACS separation buffer (Miltenyi Biotec) was added.
A cocktail containing 4 mg each of four biotinylated enrich-
ment antibodies was added to each sample and incubated for
two h at 4C on a laboratory shaker. The three commercial
enrichment antibodies were biotinylated mouse anti-human
HLA-G, biotinylated mouse anti-human TROP-2 (both Novus
Biologicals), and biotinylated mouse anti-human EpCAM
(BioLegend). The fourth antibody was developed against JEG
cell line membranes by the Protein and Monoclonal Antibody
Production Core at Baylor College of Medicine. Screening of
this antibody was performed by the Mancini lab and the Anti-
body core facility, and subsequent mass spectroscopy analysis
was used for identification of its antigen, which was EpCAM.
The fourth antibody (up to 2 mg) was biotinylated via the Light-
ning-Link Rapid Biotin Kit type A from Expedeon. Subsequently,
samples were incubated with anti-biotin magnetic microbeads
(Miltenyi Biotec) for two h at 4C on a laboratory shaker. Positive
trophoblast selection was achieved with MS columns and a
MiniMACS separator (Miltenyi Biotech). After enrichment, the
resulting cells were resuspended in BD Perm/Wash buffer (BD
Biosciences) and underwent immunostaining with two anti-
cytokeratin antibodies (both pan-CK reactive, BioLegend and
eBioScience), one antibody against the white blood cell (WBC)
marker CD45 (BioLegend), and DAPI nuclear stain (1-h incuba-
tion at room temperature).Trophoblast Isolation and Single-Cell Processing
After immunostaining, the sample was spread into CyteSlides
(RareCyte) in PBS, and these were subsequently scanned on a
CyteFinder (RareCyte). All identified trophoblast candidates were
then curated manually on the basis of specific criteria (positive cy-
tokeratin staining and its pattern, negative for CD45, nuclear
morphology) as described previously.6,9 Using the CytePicker
module (RareCyte), all putative trophoblasts were picked individ-
ually with a 40-mm diameter needle and deposited into PCR tubes
in 2 mL PBS. All cells were stored at80C until further processing.
Before downstream analysis, each cell underwent whole-
genome amplification (WGA) via the PicoPLEX WGA kit (Takara
Bio). The concentration of the amplified DNA was measured on
a Nanodrop platform.Cell Culture for Spike-in Experiments
All lymphoblast cell lines were kept in culture under normoxic
conditions (37C, 5% CO2) in fetal bovine serum (FBS)-supple-
mented RPMI 1640 culture medium. Three different lymphoblast
cell lines were included in spike-in experiments: a male line
harboring a 3.8 Mb Smith-Magenis syndrome deletion (17p11.2)
(MIM: 182290), a female line harboring a 2.5 Mb DiGeorge syn-
drome deletion (22q11.21) (MIM: 188400), and a female line
harboring a 1.3 Mb Charcot-Marie-Tooth duplication (17p12)
(MIM: 118220). Before being spiked into control blood, an aliquot
of each cell culture was labeled with both CellTracker Green
5-chloromethylfluorescein diacetate (CMFDA; Life Technologies)
and MitoTracker Orange chloromethyltetramethylrosamine
(CMTMRos; Life Technologies) according to themanufacturer’s in-
structions so that the spiked-in cells in the eventual enriched cell
suspension could be easily detected via microscopy. Single lym-
phoblasts were picked in the same manner as trophoblasts and
stored at 80C until WGA processing and further analysis.nal of Human Genetics 105, 1262–1273, December 5, 2019 1263
Table 1. Overview of Sample Characteristics for Both Studies
Parameter Study 1 Study 2
Number of samples 42 53
Average sample volume 28.5 mL, 5 3.1 mL 36.2 mL, 5 4.3 mL
Gestational age 8 weeks, 2 days to 20 weeks, 6 days (average:
13 weeks, 2 days, 5 2 weeks, 5 days)
9 weeks, 3 days to 29 weeks, 5 days (average:
13 weeks, 6 days, 5 3 weeks, 5 days)
Plurality and Fetal sex 22 F singletons/18 M singletons/2 twins
(1 FþM and 1 MþM)
20 F singletons/27 M singletons/6 twins
(4 FþM, 1 MþM, and 1 FþF)
Recruitment site 29 Houston; 13 New York 39 Houston; 14 New York
Maternal age 26–43 years old (average: 34.7 years
old, 5 3.9 years)
19–41 years old (average: 33.1 years old,
5 5.2 years)
Maternal BMI 19.0–42.7 kg/m2 (average: 26.3 kg/m2,
5 5.4 kg/m2)
18.9–41.3 kg/m2 (average: 27.3 kg/m2,
5 6.0 kg/m2)
Clinical diagnostic testing 19 procedures: 13 CVS (of which 6 blood
samples were collected post-CVS);
5 amniocentesis (none were collected
post-amnio); 1 both (sample was
collected after amniocentesis
procedure) // 23 no procedure
25 procedures: 14 CVS (of which 9 samples
were collected post-CVS); 10 amniocentesis
(of which 3 samples were collected
post-amnio); 1 both (sample was collected
after CVS procedure) // 28 no procedure
Main Indication for Genetic Counseling and/or Diagnostic Testing
AMA 23 (54.8%) 20 (37.7%)
Abnormal cell-free NIPT 3 (7.1%) 3 (5.7%)
Abnormal ultrasound 3 (7.1%) 9 (17.0%)
Parental indication (balanced translocation,
carrier)
3 (7.1%) 3 (5.7%)
Regular first trimester screen (not AMA) 3 (7.1%) 7 (13.2%)
Abnormal prior pregnancy 1 (2.4%) 3 (5.7%)
Abnormal quad screen 1 (2.4%) -
Abnormal CVS 1 (2.4%) -
Abnormal serum screen - 1 (1.9%)
Abnormal PGT result - 1 (1.9%)
Combination of 2 or 3 of the above 4 (9.5%) 6 (11.3%)
Trophoblast Yield as Identified by Microscopy
Total 226 cells 398 cells
Per sample: average 5.38 cells/sample 7.51 cells/sample
Per sample: median 3.00 cells/sample 6.00 cells/sample
Per sample: range 1–23 cells/sample 0–26 cells/sample
Per mL maternal blood: average 0.19 cells/mL 0.21 cells/mL
Per mL maternal blood: median 0.11 cells/mL 0.18 cells/mL
Number of samples with cell clusters 18 (43%) 28 (53%)
*AMA, advanced maternal age; BMI, body mass index; CVS, chorionic villi sampling; F, female; M, male; NIPT, noninvasive prenatal testing; PGT, preimplantation
genetic testing; SD, standard deviationNext-Generation Sequencing and CNV Analysis
All next-generation sequencing (NGS) was performed on WGA
products from single cells, or occasionally from cell clusters. No
single cells or WGA products from singleton or twin pregnancies
were pooled. After consecutive DNA shearing (Covaris), end repair
(New England Biolabs reagents), A-tailing (NEB), and Illumina
adaptor ligation, a round of PCR with specific Illumina primers
was performed. Once the library preparation was finished, sin-1264 The American Journal of Human Genetics 105, 1262–1273, Decgle-end sequencing (read length 100 bp) was performed for all
samples on a HiSeq 2500 platform (Illumina); the desired coverage
was 53 106 reads/sample. Sequence files were mapped against the
human reference genome (hg19) via the Burrows-Wheeler Aligner
MEM algorithm (v.0.7.15). Coverage counts were generated with
the bedtools’ (v.2.25.0) multicov function.
All generated. bam files were analyzed in NxClinical
(BioDiscovery). Each trophoblast was compared to a 3-cell pool ofember 5, 2019
Figure 1. Number of Trophoblasts Identified by Microscopy
The total number of putative trophoblasts/mL ofmaternal blood is
shown with coding according to the study and gestational age of
each sample. ‘‘Clusters’’ means that groups of two or more tropho-
blasts were detected and processed as a unit if they did not separate
during picking as described in the Material and Methods. About
55% of these cells will give NGS data that are scorable for both
aneuploidy and pathogenic CNVs. All twin pregnancies are indi-
cated with a circle.normal female trophoblast reference and to a 3-cell pool of normal
male trophoblast reference for genome-wide CNV analysis. This
software enables multiple modes of data visualization, including
whole-genome plots that allow for nucleotide-level zooming in
on the data for each cell and multi-sample views indicating the
copy-number changes automatically called within the software.
Two American Board of Medical Genetics and Genomics
(ABMGG)-certified directors (A.M.B. cytogenetic and W.B. com-
bined cytogenetics and molecular genetics) reviewed all data in a
blinded manner to score each cell for its quality and judged
whether they were scorable for both aneuploidy and smaller
CNVs (R1 Mb) detection on the basis of their NxClinical quality
score and whole-genome profile.Genotyping
Application of an in-house-developed genotyping assay confirmed
the fetal origin of the analyzed genome.9 A multiplex PCR
including 41 amplicons was run on the WGA products and
maternal gDNA (as well as paternal gDNA when available), and
the resulting products underwent MiSeq sequencing (2 3 150 bp
paired-end reads). The SNP profiles were subsequently compared
with the maternal profile. In case a fetal allele for a given SNP is
different from the maternal profile, this demonstrates the fetal
origin of the cell.Results
Trophoblast Identification and Yield
An overview of all sample information for both validation
studies is summarized in Table 1, and complete data are
provided in Table S1. For study 1, a total of 226 tropho-
blasts were microscopically identified in 42 samples with
5.38 cells/sample on average (5.08 cells/sample for single-
tons only). Recalculated as cells per mL of maternal blood
(an average volume of 28.5 mL per sample was processed),The American Jourthis is 0.19 cells/mL on average (0.18 for singletons). Cells
were found in all samples included in this study set, and
the range of trophoblasts identified per sample was 1 to
23 cells. In study 2, the blood volume was increased to
four 10 mL EDTA tubes; there was an average of 36.2 mL
per sample, and 398 trophoblasts were identified in total
in 53 samples. This number correlates to 7.51 cells/sample
on average (6.91 for singletons) and to an average of 0.21
cells/mL (0.18 for singletons). The range was 0 to 26 cells,
and this set included two samples for which no cells were
found.
Figure 1 displays the number of trophoblasts microscop-
ically identified per sample for both studies and also
indicates whether only single cells or also trophoblast clus-
ters were found. Trophoblast identification relied primarily
on cytokeratin (CK) positivity and CD45 negativity. For
study 1, clusters were found in 18/42 samples (43%); in
study 2 clusters were found in 28/53 (53%) (Table 1). The
two singleton pregnancies for whom no cells were recov-
ered in study 2 were NIPT1484, age 37 at 13 weeks 4 days
gestational age (GA) and having a BMI of 30.95 kg/m2,
and NIPT1497, age 39 at 12 weeks, 2 days GA and having
a BMI of 38.87 kg/m2. Neither of them was associated
with any unusual circumstances, and we suspect that the
number of cells recovered might be based on normal bio-
logical variation in placentation. In other studies in our
lab, fewer cells were recovered between 7 weeks, 0 days
and 10 weeks, 0 days of gestation (data not shown) and af-
ter 15 weeks of gestation. We found a statistically signifi-
cant downward trend in trophoblast cells identified with
increasing GA for these datasets: when we considered all
samples from both studies together, the correlation coeffi-
cient for cells/mL as a function of gestation was 0.36,
with a p value of 0.00032 (Spearman’s correlation, 95
singleton and twin samples in total; r ¼ 0.41 for single-
tons only, p value 7 3 105). When we divided the
singleton data into two groups, one group including sam-
ples collected at %14 weeks and 6 days (70 samples) and
one group at R15 weeks (17 samples), the mean for the
samples collected at earlier gestation (0.21 cells/mL) was
significantly higher than for those collected at later gesta-
tion (0.07 cells/mL; p value ¼ 0.00006, Mann-Whitney
test). There were considerably fewer samples collected at
a later gestation. We presume that the fewer cells recovered
at later gestations reflects normal placental development.
We conclude that SCT testing is optimally used at 15 weeks
of gestation or earlier. If used at later gestations, physicians
and patients should be aware of a lower success rate.
Maternal BMI data were available for 85 out of the
95 samples; the average maternal BMI was 26.8 kg/m2
(range ¼ 18.9–42.7). Although there was a downward
trend for cell recovery with increasing BMI, the difference
was not statistically significant (Spearman’s r ¼ 0.203,
p ¼ value 0.063; r ¼ 0.206 for singletons only,
p value ¼ 0.071). No correlation was found with maternal
age (Spearman’s r ¼ 0.05, p value ¼ 0.657; all singleton
and twin pregnancies were included).nal of Human Genetics 105, 1262–1273, December 5, 2019 1265
In total, 44 women underwent CVS or amniocentesis.
Although blood draw prior to procedure was recommen-
ded, for 20 of those, the blood sample could only be
collected shortly after the procedure (within minutes to
up to two h). However, there was no statistically significant
difference in trophoblast yield when blood samples
collected after CVS or amniocentesis were compared to
all other samples (Mann-Whitney; p value 0.960). Re-
sources did not permit following up on all infants at birth.
Therefore, conclusions about accuracy of SCT testing were
made only on the basis of data from the pregnancies where
CVS or amniocentesis was also performed. There were two
samples (NIPT1310 and NIPT1312) where the SCT test
result showed trisomy 21 and the cell-free NIPT result indi-
cated trisomy 21, and both pregnancies were terminated
on the basis of cell-free NIPT and ultrasound findings
without CVS, amniocentesis, or product of conception
testing. These were not included in calculating accuracy.Confirmation of Fetal-Cell Origin
For the total of 149 putative trophoblasts analyzed from
confirmed male singleton pregnancies, nine cells were
found to be of maternal origin by the presence of a
46,XX complement on their next-generation sequencing
(NGS) profile. Thus, 94% of cells scored microscopically
as fetal were male. For pregnancies with a female fetus,
all cells were genotyped so that maternal origin could be
distinguished from fetal origin as previously described.6,9
For 155 cells that were judged to be female on the basis
of their CNV analysis result and that came from pregnan-
cies with a female fetus or twins, genotyping confirmed
that 149 (96%) were of fetal origin.Twin Pregnancies
In total, eight twin pregnancies were analyzed, as detailed
in Table S2: five dichorionic-diamniotic opposite-sex twin
pairs, two male-male pairs (one dichorionic-diamniotic
and one monochorionic-diamniotic), and one dichor-
ionic-diamniotic female-female twin pregnancy. Not unex-
pectedly, we found a higher cell number for these twin
pregnancies: the average for all eight twin pregnancies
was 13.5 cells/sample and 0.41 cells/mL (versus 0.18 for
singletons). The range of trophoblasts microscopically
identified was 3–26 cells/sample, or 0.11–0.77 cells/mL.
When comparing these values to the group of 87 singleton
samples, we found the difference to be significant with a p
value of 0.001 (Mann-Whitney test).
For NGS analysis on twins, a minimum of five cells per
sample was included, except for one sample (NIPT1432, fe-
male-male twin pair) for which only one female doublet
was available for downstream analysis. For three other
opposite-sex twin pairs, cells from both the male and fe-
male fetuses were recovered, whereas for the fifth twin
pregnancy (NIPT1441) 10 cells were analyzed, and all
were female. Cells from both sexes from one of the oppo-
site-sex twin pairs are illustrated in Figure 2A.1266 The American Journal of Human Genetics 105, 1262–1273, DecNGS Analysis and Single-Cell Quality
Single-cell sequencing data can vary considerably in terms
of quality. We found some cells to be in a state indicative of
apoptosis on the basis of their sequencing profile. As re-
ported previously,9 apoptotic cells have widely variable
copy number; often entire chromosomes vary such that
there are chromosomes with 2, 1, and even 0 copy number.
This is consistent with published evidence that chromo-
somes are often degraded as entire domains in apoptotic
cells.10 For study 1, this was the case for 9.3% of analyzed
cells; for study 2, this was the case for 6.67% of cells. Addi-
tionally, the profile for a portion of cells suggested that
these were in the S phase of the cell cycle. We interpreted
cells with a bimodal copy number across the entire genome
as indicative of S phase, which is illustrated in Figure 2B
(cell G1491). For cells in late S phase, yet-to-be-replicated
regions were indistinguishable from what might be small
deletions across the entire genome. We saw an indication
of S phase for 11.0% of the cells analyzed in study 1, and
for 17.1% of the cells in study 2. Upon analysis, we found
that these S-phase cells are still adequate for aneuploidy
scoring in more than 90% of cells (Figure S1).
The NGS data for all samples were scored by two ABMGG
certified lab directors as pass or fail for aneuploidy and for
smaller copy-number variants of R1 Mb. Cells that were
scorable for both aneuploidy and R1 Mb deletions and/or
duplicationswere consideredhigh-quality cells. For thefirst
study, 1.62 high-quality cells/sample were obtained; this
numberincreased to 2.17 high-quality cells/sample for the
second sample series. All scoring was blinded, but
reviewers did know which cells were from the same
pregnancy. Additional information they were provided
included which pregnancies involved twins, the fetal sex
as predicted by the cfDNA Y-PCR assay carried out as part
of the SCT test, and the ultrasound-determined sex when
available. The scores of the two reviewers were 89.0%
concordant for pass/fail scores for each cell. The reviewers
also scored every passing cell as normal (possibly including
benign CNVs), aneuploid, or pathogenic CNV, and there
was 100% concordance on these scores. All CNVs observed
were previouslywell characterizedwithno rareCNVs of un-
certain significance found. A common variant of uncertain
significance (VUS) of deletion 15q11 (BP1-BP2) was
observed in one instance. Out of all 95 samples included
in the two studies, 52.6%had at least two high-quality cells
that were scorable for both aneuploidy and smaller CNVs.
As shown in Table 2 and Figure 3, out of all 32 singleton
samples that were collected before 15 weeks of gestational
age (because those have a better trophoblast yield), 56.3%
had at least two high-quality cells for study 1, whereas for
study 2 63.2% (38 pregnancies total) had at least two
high-quality cells; the difference between the studies was
primarily related to collection of a larger volume of blood
in study 2. In 28.1% and 21.1% of samples in study 1 and
study 2, respectively, only one high-quality cell was found.
For 9.4% and 5.3%, only lower-quality data adequate for
aneuploidy calling but not for smaller CNV detectionember 5, 2019
Figure 2. Single-Cell NGS Analysis and
Single-Cell Quality
(A) Multiple cells from an opposite-sex
twin pair are demonstrated. Each cell is
compared to a normal female control,
and a loss of X (red arrows) and gain in Y
(blue arrows) is seen for three male cells.
All cells shown were judged to be scorable
for both aneuploidy and pathogenic
CNVs. All cells were genotyped as fetal,
and the two female cells are from the other
twin. The clinical result for both twins was
interpreted as normal.
(B) An example of a single S-phase cell
compared to a cell not in S phase. The fetus
is male, and both cells are compared to a
normal female control. The upper cell is
judged to be scorable for both aneuploidy
and pathogenic CNVs, whereas the lower
cell is judged to be in S phase and scorable
for aneuploidy but not for CNVs.were obtained, and for 6.3% and 10.5% of pregnancies no
usable data at allwere available. Similar data for pregnancies
after 15 weeks of gestation showed that the success rate was
much lower (Table S3).
Correlation with Normal and Abnormal Diagnostic
Results Obtained from Amniocentesis or CVS
After completion of the SCT analysis, including a blinded
final clinical interpretation, we reviewed the available clin-
ical data and CVS and/or amniocentesis results for confir-
mation. All samples were given overall scores as normal,
aneuploid, pathogenic CNV, or failed, and the overall score
that each reviewer gave for all samples in which there was
at least one high-quality cell was 100% concordant withTable 2. NGS Results for All Singleton Pregnancies at <15 Weeks of Gestational Age
NGS Result Study 1
Total pregnancies 32
R2 high-quality cells 17 pregnancies (53.1%)
1 high-quality cell 10 pregnancies (31.3%)
Aneuploidy data only 3 pregnancies (9.4%)
No usable data 2 pregnancies (6.3%)
The American Journal of Human Geneticsthe clinical data. There were also no
examples of discordant findings in
cells from same-sex twins. For study
1, 19 out of 42 pregnant women also
underwent CVS and/or amniocen-
tesis, whereas for study 2 this was 25
out of 53. For 33 out of these total
44 pregnancies, with complete data
for both SCT testing and either
amniocentesis or CVS (or both), and
no evidence of mosaicism, there was
complete concordance (27 normaland 6 aneuploidy; Tables 3 ). For eight cases, the CVS
and/or amniocentesis results were normal, and the SCT
testing failed (either there were no cells available for
sequencing or sequenced cells did not yield any usable
data). As discussed further below, the three remaining
pregnancies had SCT findings that we interpret as confined
placental mosaicism (CPM), whereas CVS and/or amnio-
centesis results were normal (Tables 3 and 4). If one focuses
on the 33 pregnancies where adequate data from both SCT
testing and either amniocentesis or CVS were available,
both the sensitivity and the specificity were 100%. This ex-
cludes eight samples where SCT failed, and three that we
interpret as likely to be CPM. For the 44 cases with CVS
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Figure 3. Yield of High-Quality Cells for Both Studies
These two graphs show the number of high-quality cells, i.e., two
blinded reviewers judged each cell as scorable for both aneuploidy
and pathogenic CNVs, for both validation sample series, accord-
ing to the gestational age at sample collection. A maximum of
five cells were sequenced, except that for twins all cells were
sequenced.18.1% (8/44). At least two cells were analyzed for 23 of
those 44 pregnancies (52.3%); each cell from a particular
pregnancy showed the same result. For nine cases (eight
normal pregnancies and the trisomy18 pregnancy), there
was only one cell available for analysis.
Multiple fetal aneuploidies confirmed by diagnostic
testing were part of these sample series: four instances of
trisomy 21, one instance of trisomy 18, and one fetus
with a 47,XXY karyotype. One trisomy 21 example is
shown in Figure 4A, illustrating the whole-genome plots
of five different trophoblasts obtained for this case. Of
note, the third cell in this example showed a pattern indic-
ative of S-phase as described earlier, but it still clearly shows
the trisomy.
Confined Placental Mosaicism
As stated above, we found three instances of likely
confined placental mosaicism (CPM) over the course of
these two studies. For subject NIPT1309, the cell-free
DNA-based screening test was positive for trisomy 13,
whereas the follow-up CVS (both direct and cultured cells)
showed a normal 46,XY profile by karyotype and chromo-
somal microarray (CMA). Ultrasound examination did not
show any fetal abnormalities. The two trophoblast cells
that were isolated from the SCT sample both showed a
trisomy 13 profile. In a second pregnancy, NIPT1449
(Figure S2A), the cell-free DNA-based test had indicated
‘‘an increased risk for monosomy X.’’ Subsequent chromo-
some analysis on cultured CVS and FISH on direct CVS
showed a normal 46,XX complement, and no follow-up
amniocentesis was performed. No abnormal findings on
ultrasound examination were reported. The seven scorable1268 The American Journal of Human Genetics 105, 1262–1273, Dectrophoblasts isolated from two different SCT blood sam-
ples indicated a mosaic result: four showed a normal
46,XX complement, whereas the other three cells showed
a 45,X profile. It is of interest to note that an unusual num-
ber of poor-quality cells were found for this pregnancy: of
those seven scorable cells, only four were of high quality,
and another three were only scorable for aneuploidies.
The remaining six cells were not scorable. For another sam-
ple (NIPT1489; Figure S2B), an unequivocal trisomy 15 was
seen in the only trophoblast doublet obtained. The cell-
free DNA-based testing showed a normal result, as did
the amniocentesis analysis (direct and culture; karyotype
and CMA were performed). Several fetal anomalies,
including clubfoot, horseshoe kidney, and hydrocephalus,
were noted on ultrasound examination.SCT Testing: CNV Resolution
There were no pregnancies involving a clinically diagnosed
pathogenic CNV in these studies. Several benign CNVs
frequently seen in polymorphic and repetitive regions
around centromeres were reproducibly detected with our
method (Figure 4B top left). For purposes of quality assur-
ance and calibration for detection of deletions and duplica-
tions, we spiked into non-pregnant blood small numbers
of lymphoblasts with known deletions or duplications.
For lymphoblasts carrying a 3.6 Mb Smith-Magenis syn-
drome deletion, the deletion was detected in 100% of 26
cells with high-quality data (Figure 4B, top right). For
DiGeorge syndrome lymphoblasts with a 2.7 Mb deletion,
the deletion was detected in all nine high-quality cells
(Figure 4B, lower left). For single lymphoblasts harboring
the 1.3 Mb Charcot-Marie-Tooth type 1A duplication, the
duplication was detected in 75% of 16 cells of high quality
(Figure 4B, lower right).Discussion
The isolation and analysis of single circulating fetal or
trophoblast cells could revolutionize the field of prenatal
diagnosis because these cells offer an optimal source of
fetal DNA. Although they are considered rare cells, multi-
ple proof-of-principle publications have shown the value
and feasibility of cell-based NIPT.6–8 In performing two
SCT-testing validation studies, we report a yield of identi-
fied trophoblasts as 1.62 fully scorable cells/sample for
the first sample series and 2.43 high-quality cells/sample
for the second study. For these two studies, the downward
trend in trophoblast recovery with increasing gestational
age was found to be statistically significant. The increase
in trophoblasts at an earlier gestational age could be ex-
plained by the process of trophoblast invasion’s leading
to necessary uterine vascular remodeling during preg-
nancy.11 These invading trophoblasts enter the maternal
veins andmight in this manner end up in thematernal cir-
culation.12 The trophoblast invasion process starts around
6–8 weeks of gestation and is generally completed by 19 orember 5, 2019
Table 3. Forty-Four Pregnancies with Available CVS or
Amniocentesis Data
SCT Testing CVS and/or Amniocentesis Analysis
27 normal results 27 normal results
6 aneuploid results* 6 aneuploid results
8 failed analyses 8 normal results
3 mosaicism 3 normal results
*Included in the aneuploidy results were four trisomy-21 pregnancies
(NIPT1303, NIPT1322, NIPT1336, and NIPT1443), one trisomy-18 pregnancy
(NIPT1298), and one 47,XXY pregnancy (NIPT1501).20 weeks of gestation,11 hence possibly leading to a
decreased trophoblast yield at a later gestational age. No
significant correlation between maternal age and tropho-
blast yield was seen, and maternal BMI did not affect the
yield significantly; in contrast, a stronger negative correla-
tion with BMI was seen with cell-free DNA-based testing,3
although a slight downward trend in the number of tro-
phoblasts was noted with increasing BMI. Another study
also found a very weak trend toward lower cell numbers
as BMI increased.13 Those authors concluded that ‘‘cell-
based NIPT should not be hampered by an increased
BMI.’’ The much-reduced effect of BMI on test perfor-
mance is an important potential advantage of SCT testing
over cell-free NIPT.
Focusing on the analysis of single trophoblast cells, we
can learn several lessons from these studies. First, as we
have shown before,9 it is critical to analyze each tropho-
blast individually because the quality of single cells can
vary substantially. Some cells are in an apoptotic state
involving genome-wide degradation and loss of chromo-
some arms or whole chromosomes. Apoptosis of tropho-
blasts in the maternal circulation is well described,14 and
there was little way to anticipate what the frequencymight
be. Pooling apoptotic cells with high-quality trophoblasts
prior to amplification would severely impact the overall
result.9 Additionally, a few percent of cells are found to
be in S phase, which also results in a disturbed whole-
genome pattern because some parts of the genome will
already have replicated before other parts, and the non-
replicated regions can be misinterpreted as deletions.
This phenomenon has been described earlier by Dimitria-
dou et al.,15 who concluded that a cell’s being in S phase
can interfere with accurate CNV calling for the purpose
of preimplantation genetic diagnosis. They illustrated
that duplications from 9 to 25 Mb and deletions of 8 MbTable 4. Pregnancies Interpreted as Having Confined Placental Mosa
Sample GA U/S cfNIPT CVS and
NIPT1309 12 weeks, 1 day normal T13 direct & c
NIPT1449 13 weeks, 3 days and
14 weeks, 2 days
normal monosomy X direct & c
NIPT1489 20 weeks, 2 days abnormal normal amnio no
The American Jourwere potentially missed in this scenario. Our results agree
that these cells are inadequate for reliable CNV calling by
NGS, but we found that S-phase cells are often still scorable
for aneuploidy calling, as was seen in several of our trisomy
cases (Figure S1). The preliminary validation studies per-
formed here demonstrate that it is feasible to obtain multi-
ple trophoblasts scorable for both aneuploidy and CNVs in
more than half of all pregnancies tested. In the second
study, which involved drawing 40 mL of maternal blood,
two or more scorable cells were recovered in 57% of all
pregnancies. Of note, for singleton pregnancies for which
more than five cells were obtained, we did not perform
NGS analysis on more than five cells. A central question
is what number of scorable cells might represent an
adequate result for clinical interpretation and a lab report.
Although we began with a goal of three to five scorable
cells per sample, it became clear that multiple pregnancies
yielded only one, two, or occasionally zero high-quality
cells—this remains an important limitation of our test.
However, based on the very high concordance of multiple
cells from individual singleton pregnancies, we become
relatively confident of the accuracy of the clinical
interpretation when two cells are found scorable by two in-
dependent, blinded, board-certified reviewers with full
agreement on the conclusions. This does not rule out
mosaicism.
Second, adequate genotyping of each trophoblast is
essential. Despite our extensive experience and the appli-
cation of strict criteria for trophoblast candidate selection
by microscopy, occasionally a putative trophoblast cell
was found to be of maternal origin. In the case of a male
fetus, the confirmation is straightforward because an XY
profile is clear from the whole genome plot obtained for
CNV analysis, and 94% of all analyzed cells from a known
male fetus were confirmed to be male. For female fetuses,
single trophoblast genotyping needs to be built into the
workflow so that that all analyzed cells are guaranteed to
be of fetal origin. Of note, the probability that putative tro-
phoblasts are of true fetal origin is higher when the cells
appear in clusters, and we usually did not see these clusters
for maternal cells.
Third, the results of analysis of multiple cells from the
same pregnancy are remarkably consistent unless there is
evidence of placental mosaicism or a multiple pregnancy.
The ability of SCT testing to detect various forms of mosa-
icism is an important consideration. There are three types
of CPM (types I, II, and III) and three types of true fetal
mosaicism (TFM) (types IV, V, and VI);16 types I and II areicism
/or Amnio SCT Testing
ulture CVS normal (karyotype & CMA) 2/2 cells trisomy 13
ulture CVS normal (karyotype & FISH) 4 cells 46,XX & 3 cells 45,X
rmal (karyotype & CMA) 1/1 cell trisomy 15
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Figure 4. Examples of Aneuploidy and Subchromosomal CNV Detection
(A) The NGS result of five single trophoblasts for a pregnancy in which the fetus was affected with trisomy 21. The clinical diagnosis was
made by karyotype and chromosomalmicroarray after CVS. These plots were generated by comparison to a normal female reference cell.
Cell G730 was judged to be in S phase and not scorable for smaller CNVs, although the trisomy is obvious despite the noise. The first
(legend continued on next page)
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the most common forms of CPM overall. CPM is not al-
ways benign; in a recent study on types II and III, the latter
was found to be significantly associated with preterm
births, newborns who were small for their gestational
age, and adverse pregnancy outcomes.17 Both types II
and V involve mesenchymal cells only and would thus
not be detected by our SCT assay, which only examines cy-
totrophoblastic cells. In our 95-sample series, we encoun-
tered three instances of likely CPM, and these were most
compatible with type I CPM. In two of those pregnancies
there was independent evidence for the presence of CPM
from other clinical results. For the third pregnancy, we
interpret the recovery of the only cell showing trisomy
15 from a pregnancy with a normal cell-free NIPT and
amniocentesis outcome as most likely originating from
low-level CPM. Although mosaicism overall is detected in
about 2% of CVS analyses and 1% for CPM type I specif-
ically, the gestational age and the number of cells studied
can affect detection rates. Hence, in this situation, pursu-
ing a confirmatory CVS or amniocentesis would be recom-
mended. The time frame for SCT testing, however, is of
great advantage because it can be done early enough in
the pregnancy to allow ample time for follow-up testing.
Several samples collected at 10 weeks of gestation or earlier
were included in this study and produced satisfactory re-
sults, and we are currently collecting more samples as early
as 6 or 7 weeks of gestational age. It is also important to
note that other factors, such as ultrasound examination,
will help in evaluating a SCT test result.
Fourth, the analysis of multiple pregnancies can prove a
challenging task, but SCT testing has advantages over cell-
free DNA-based NIPT because each fetus can be tested
separately. Although, in general, a higher number of tro-
phoblasts is obtained for multiples, this does not guarantee
recovery of cells from all fetuses. If twins are of opposite
sexes, it is straightforward to determine which cells are
from which fetus. Although for three out of the five oppo-
site-sex twin pregnancies described here cells from both
twins were analyzed, for the two other pregnancies data
were available for only one fetus, indicating that more
method improvements for twin analysis are necessary.
Our current method is also limited in the sense that the
zygosity of the multiples is not determined and that it is
not always possible to track from which fetus a certain
trophoblast originated (e.g., when both twins are of the
same sex and/or when no obvious ultrasound findings
can give any indication). Nevertheless, SCT testing can still
offer valuable information on twin and multiple pregnan-
cies because each trophoblast is analyzed and evaluated
separately. A DNA sample from the father is not needed
for SCT testing unless there is a question of whether a
finding in the fetus is de novo or inherited.example in (B) shows a detailed view of a trophoblast from a pregnan
which is a benign, recurrent polymorphism, as frequently seen in ou
lymphoblast carrying a 3.6 Mb Smith-Magenis deletion (SMS), a 2.7
duplication (CMT1A).
The American JourFinally, our method allows reliable detection of CNVs
down to 1 Mb in size, as we illustrated previously,9 and is
here confirmed again by the detection of small, benign,
recurrent CNVs (Figure 4). Although these pericentromeric
repetitive sequences are often excluded in microarrays,
these regions were included in the NGS analysis if reads
could be uniquely mapped in the genome. We have also
shown that the use of spiked-in single lymphoblast cells
can be very helpful for quality assurance regarding detec-
tion of CNVs of various sizes.
It is difficult to compare these results to the National
Institute of Child Health and Human Development Fetal
Cell Isolation Study (NIFTY) study from 17 years ago.18
That study focused on fetal nucleated red blood cells and
fluorescence in situ hybridization (FISH) detection of aneu-
ploidy, whereas this study focuses on trophoblasts and
detection of CNVs down to 1–2 Mb. Putting aside these
major differences, the NIFTY study found ‘‘at least one
aneuploid cell in 74.4% of cases of fetal aneuploidy,’’
whereas this study found at least one aneuploid cell in
100% of affected fetuses.
The results from SCT testing are all-or-none conclusions,
such as whether a particular aneuploidy or pathogenic
CNV is present or absent in the cell being analyzed. This
is similar to cytogenetic chromosomal microarray data
and can thus be considered a qualitative result, more char-
acteristic of a diagnostic test. In contrast, cell-free NIPT can
only provide a probability that a particular aneuploidy or
pathogenic CNV is present or absent, and this limited abil-
ity is more characteristic of a screening test.
We have mentioned a number of limitations, including
the inability to obtain high-quality data for multiple cells
from every fetus. Some cells are apoptotic or in S phase,
but because all cells are analyzed individually, these cells
do not interfere with the interpretation of high-quality
cells. Although the request was to draw blood prior to
CVS or amniocentesis, this was not always achieved in
the busy clinic environment. We did not find a significant
difference in cell recovery when blood was drawn either
before or after CVS (in 12 cases prior to, in 16 after CVS)
or amniocentesis (12 prior to, four after), but the number
of samples is low and too small to allow comparison of
the effect of length of time between the procedure and
blood draw. The detection of CPM can bring both some ad-
vantages and some disadvantages. Detecting mosaicism in
general is an advantage because it provides information
about the fetus, such as providing the opportunity to
detect uniparental disomy or true fetal mosaicism and
could easily be followed up with CVS and/or amniocen-
tesis. Our method differs from CVS in that it fails to detect
mesenchymal CPM. Although the current higher costs and
limited throughput may be disadvantages initially, wecy in study 2. Chromosome 15 has a 2.5 Mb centromeric deletion,
r NGS data. The other three plots show the NGS result for a single
Mb DiGeorge deletion (DGS), and a 1.3 Mb Charcot-Marie-Tooth
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believe that these limitations can be solved through (tech-
nical) improvements and automation.
Is the test clinically useful in its present form? Opinions
are likely to differ. We estimate that the cost of testing with
the current protocol would be at least $3,000, and the
throughput would be a constraint. We expect that im-
provements could lower costs and increase throughput
substantially. The turnaround time would be 2–3 days
longer than that for cell-free NIPT. In light of the 15.8%
no-result rate for CNVs and the 10.5% no-result rate for
aneuploidy in study 2 as shown in Table 2, there is clear
need for improvement. Any test failures could be followed
up through CVS or amniocentesis. Although the recovery
of two or more high-quality cells from >95% of fetuses
would make the test more ready for clinical use, even in
its current form it could be an attractive clinical option
for early testing of pregnancies at high risk.
In conclusion, SCTanalysis is potentially a powerful tool
for prenatal testing and diagnosis. We are optimistic that
the recovery of trophoblasts can be improved. SCT testing
has the potential to deliver a diagnostic result instead of
being merely a screening test if an adequate number of
trophoblast cells can be obtained for every sampled preg-
nancy. A longer-term goal would be to detect all de novo
point mutations in a fetus.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
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